inquiry@market.us
+1 718 874 1545 (International)
+91 78878 22626 (Asia)
Search...
All Reports
All Sectors
Who Trust Us
Home ➤ Life Science ➤ Therapeutics ➤ CAR-T Cell Therapies Market
Global CAR-T Cell Therapies Market By Drug Type (Axicabtagene Cilolecucel,
Tisagenlecleucel, Brezucabtagene Autoleucel, Brexucabtagene Autoleucel,
Lisocabtagene Maraleucel), By Modality (Research and Commercialized), By
Target Antigen (CD19, CD22, BCMA, and Others), By Indication, By End-User, By
Region and Companies - Industry Segment Outlook, Market Assessment,
Competition Scenario, Trends, and Forecast 2024-2033
Published date: Feb 2023
Report ID: 105628
Number of Pages: 310
Inquiry Before Buying
Mention interested
topics/company profiles.
Format:
Enter Name
Overview
Table of Contents
Major Market Players
Request a Free Sample
Enter Email ID
-Select Country-
Quick Navigation
Report Overview
The Global CAR-T Cell Therapies Market size is expected to be worth around USD 10.2 Billion by
2033, from USD 2.8 Billion in 2023, growing at a CAGR of 13.8% during the forecast period from
Enter Phone Number
Enter Company Name
Submit
2024 to 2033.
Report ID
105628
Published Date
Feb 2023
Rating
★ ★ ★ ★ ★ (46)
add_shopping_cart Buy Now
Trusted by more than 17382
organizations globally
CAR-T Cell therapies are the type of cancer immunotherapy treatment that used immune
cells called T cells, that are genetically changed in a lab to allow them to locate and destroy
cancer cells more effectively. Chimeric antigen receptors are used to kill the cancer. CAR T-cell
therapies are approved by the US Food and Drug Administration (FDA) to treat some types of
lymphomas and leukemia’s, along with various myeloma. There are three main steps included
in CAR T cell therapy which consist of engineering T cells, collecting T cells, and infusing the
CAR T cells in the human body.
Key Takeaways
Market Growth: Expected to surge from USD 2.8 Billion in 2023 to USD 10.2 Billion by 2033,
exhibiting a notable 13.8% CAGR during 2024-2033.
Drug Type Dominance: Axicabtagene Ciloleucel Dominates with a 34.4% market share in
2023, propelled by FDA approval for large B-cell lymphoma treatment.
Modality Dominance: The research segment holds a 71.5% market share in 2023,
showcasing active research institution participation and numerous products in clinical
development.
Target Antigen Dominance: CD19/CD22 Antigens Lead with a 53.9% market share in 2023,
showing efficacy in treating B-cell malignancies.
Indication Dominance: Lymphoma claims a 57.1% market share in 2023, driven by FDAapproved CAR-T cell therapies for various lymphoma forms.
End-User Segment: Hospitals dominate with a 62.8% market share in 2023, owing to
advanced facilities, capabilities, and increased patient admissions.
North America Impact: North America contributes 61.49% to the market, holding a USD
1.8 Billion value in 2023, driven by chronic disease burden and robust R&D activities.
Driving Factors
Increase in Prevalence of Cancer is the Major Factor Driving the Market Growth
North America had the maximum cancer prevalence ratio in 2020, from twelve months. The 12month prevalence rate for each cancer in North America was 588 per 100,000 population. The
increasing number of adults and children developing cancer is projected to rise in demand for
effective and consistent therapeutic treatment methods for the enhancement of the quality of
patients’ lives.
One of the significant factor driving the market growth is that CAR- T cell therapies require
short treatment to administered with a single infusion that may need at the most, two weeks’
impatient care. For example, the WHO published a fact sheet according to which, each year
around 400,000 children are develop cancer February in 2022, and 2.26 Mn cases of breast
cancer were found in 2021, worldwide.
Restraining Factors
High Cost of CAR-T Cell Therapy Hinder Market Growth
The high cost related with CAR-T cell therapy is the significant factor hampering the market
growth. The cost of CAR-T cell therapies is influenced by various factors such as the complex
manufacturing process, specialized requirements of healthcare and the personalized nature
of the therapy.
Drug Type Analysis
Axicabtagene Ciloleucel Segment to Witness Significant Growth
The global CAR-T cell therapies market is classified into axicabtagene ciloleucel,
tisagenlecleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, and others. The
axicabtagene ciloleucel segment accounted for the highest market revenue share of 34.4% in
2023, due to the rise in approval of axicabtagene cilolecucel medicine for the treatment of
relapsed or refractory large B- cell lymphoma, replaced or refractory follicular lymphoma.
For instance, in April 2022 FDA approved axcibtagene ciololeucel for adults with large B-cell
lymphoma that is refractory to first- line chemoimmunotherapy.
The brexucabtagene autoleucel segment is projected to witness the highest CAGR over the
forecast period, due to increase in adoption of CAR-T cell therapies medicine in various
countries for refractory B- cell precursor acute lymphoblastic leukemia.
Modality Analysis
Research Segment Dominated the Market and holds 71.5% Share in 2023
On the basis of modality, the global CAR-T cell therapies market is segmented into research
and commercialized. Among these, the research segment hold the 71.5% market share in 2023,
due to the highest number of CAR-T cell therapy products in the clinical development phase.
Various research institutions including Mayo Clinic are actively participating in operating CAR
-T cell therapies programs, is promoting the approach as a better way to control cancer.
The commercialized segment is estimated to witness maximum growth during the forecast
period, due to the rising product approval from the regulatory bodies to fuel the commercial
use of CAR-T cell therapies in hospital and clinical settings.
Target Antigen Analysis
CD19/CD22 Segment Accounted 53.9% Market Share in 2023
Based on target antigen, the global CAR-T cell therapies market is divided into CD19, CD22,
BCMA, and others. The CD 19/CD22 target antigens segment accounted 53.9% market share in
2022. The CD19 has produced impressive results in treating patients with B-cell malignancies.
The BCMA segment is expected to witness significant growth during the forecast period.
Indication Analysis
The Lymphoma Segment Dominates the Market Growth of the CAR-T Cell Therapies Market
Based on indication, the global CAR-T cell therapies market is segmented into lymphoma,
acute lymphatic leukemia, autoimmune disorders, and others. The lymphoma segment
dominated the maximum market revenue share of 57.1% in 2023, due to the higher number of
approved CAR- T cell therapeutics for the treatment of different forms of lymphoma with a
large number of target population. The FDA has approved various CAR-T cell therapies for
lymphoma. CAR-T cell therapies that target CD19 have advanced the treatment of multiply
replaced large B-cell lymphoma.
The acute lymphatic leukemia segment is anticipated to witness the fastest growth rate
during the forecast period. These drugs are used for the treatment of acute lymphoblastic
leukemia related to testing blood cancer.
End-User Analysis
The Hospitals Segment Holds the Highest Market Revenue Share During the Forecast Period
Based on end-users, the global CAR-T cell therapies market is classified into hospitals, cancer
research institutes. Among these, the hospital’s segment dominated the highest market
revenue share of 62.8% in 2023, owing to factors such as well-equipped operation theatres,
advanced buying power, and an increase in patient admission.
The cancer research institutes segment is anticipated to grow at the highest CAGR, due to the
accessibility of vast range of treatments of choice and rise in the number of cancer centers in
some emerging countries.
Key Market Segments
By Drug Type
Axicabtagene Ciloleucel
Tisagenlecleucel
Brexucabtagene Autoleucel
Lisocabtagene Maraleucel
Other Drug Types
By Modality
Research
Commercialized
By Target Antigen
CD19
CD22
BCMA
Other Target Antigens
By Indication
Lymphoma
Acute Lymphocytic Leukemia
Autoimmune Disorders
Other Indications
By End-User
Hospitals
Cancer Treatment Centers
Growth Opportunity
Increase in Awareness About Novel Medicine
Increasing awareness and rise in adoption of novel medicine of CAR-T cell therapies and
favorable drugs present in pipelines are estimated to provide significant opportunities for the
market. The rapidly enhancing clinical trial activities and current commercialization of CAR-T
cell therapy, which is anticipated to offer major opportunities for market growth. Additionally
increasing R&D investments from major companies offers significant opportunities for market
growth.
Latest Trends
Increasing Number of Product Approvals is one of the Global Trends in the Market
One of the rising trends in the market is the increasing number of product approvals. The
development and use of CAR-T cell therapies have revolutionized cancer treatment.
Additionally, researchers are focusing on enhancing safety and efficacy of CAR-T cell
therapies. This includes developing strategies to lower side effects.
For instance, In July 2022, Novartis AG announced KYMRIAH® (tisagenlecleucel) a CD19directed genetically altered related T cell immunotherapy indicated for the treatment of
patients up till 25 years with B-cell precursor acute lymphoblastic leukemia that is refractory
or in second or later relapse. Moreover, according to the Food and Drug Administration, two
chimeric antigen receptor-T (CAR-T) cell therapies were approved for advanced lymphoma
and acute lymphoblastic leukemia.
Regional Analysis
North America Dominates the Global CAR-T Cell Therapy Market During the Forecast Period
North America accounted for a significant CAR-T cell therapy market revenue share of 61.49%
and holds USD 1.8 Billion market value for the year. Due to rising burden of chronic diseases
such as autoimmune disorders and cancer, growth in R&D activities, and strong key players.
The accessibility of approved therapeutics with higher acceptance of CAR t cell therapies. For
Example, according to the American Cancer Society estimated that the numbers of novel
cancer cases and deaths are 1,958,310 and 609,820 cancer death in the North American
region. Additionally, various strategic are contributed by the key players.
The Asia-Pacific market is anticipated to hold the maximum revenue share during the forecast
period, due to the increase in consciousness regarding CAR T-cell therapy and rising number
of target population.
Key Regions
North America
The US
Canada
Mexico
Western Europe
Germany
France
The UK
Spain
Italy
Portugal
Ireland
Austria
Switzerland
Benelux
Nordic
Rest of Western Europe
Eastern Europe
Russia
Poland
The Czech Republic
Greece
Rest of Eastern Europe
APAC
China
Japan
South Korea
India
Australia & New Zealand
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Rest of APAC
Latin America
Brazil
Colombia
Chile
Argentina
Costa Rica
Rest of Latin America
Middle East & Africa
Algeria
Egypt
Israel
Kuwait
Nigeria
Saudi Arabia
South Africa
Turkey
United Arab Emirates
Rest of MEA
Key Players Analysis
The key players are focusing on R&D activities to develop novel CAR T-cell therapies products
for the treatment of several types of cancer. The increasing number of market players in CART cell therapies market is estimated to rise in the competitive struggle in the market.
Some of the prominent key players in the CAR T-cell therapies market include Pfizer Inc.,
Amgen Inc., Gilead Sciences, Inc., Merck & Co., Inc., Bluebird Bio, Inc., Bristol-Myers Squibb
Company, Juno Therapeutics, Inc., and other key players.
Market Key Players
Juno Therapeutics, Inc.
Bristol-Myers Squibb Company
Bluebird Bio, Inc.
Gilead Sciences, Inc.
Merck & Co., Inc.
Pfizer, Inc.
Sorrento Therapeutics, Inc.
Merck KGaA
Amgen Inc.
Eureka Therapeutics Inc.
Calyxt Inc.
Autolus Therapeutics
CARsgen Therapeutics Co.Ltd.
Poseida Therapeutics, Inc.
Fortress Biotech, Inc.
Other Key Players
Recent Development
In October 2023, Gilead Sciences, Inc. completed a significant acquisition by purchasing
Kite Pharma for $5.4 billion. This move granted Gilead access to Yescarta, the leading
CAR-T therapy designed for treating large B-cell lymphoma.
In September 2023, A major collaboration took place between Pfizer Inc. and Allogene
Therapeutics. The two companies joined forces in a $3 billion agreement aimed at
developing allogeneic CAR-T cell therapies. This collaboration is expected to provide “offthe-shelf” treatments for various medical conditions.
In August 2023, Merck & Co., Inc. marked its entry into the CAR-T market with the launch
of Abcema (idecabtagene vicleucel), a CAR-T therapy specifically designed for multiple
myeloma.
In July 2023, Bluebird Bio, Inc. shared positive results from the Phase 2 clinical trial of
bb2122, its CAR-T therapy for pediatric acute lymphoblastic leukemia (ALL). The trial
showcased high remission rates and durable responses, indicating promising outcomes
for the treatment.
Report Scope
Report Features
Description
Market Value (2023)
US$ 2.2 Bn
Forecast Revenue
US$ 7.9 Bn
(2033)
CAGR (2024-2033)
13.8%
Base Year for Estimation
2023
Historic Period
2018-2022
Forecast Period
2024-2033
Report Coverage
Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive
Landscape, Recent Developments
Segments Covered
By Drug Type- Axicabtagene Ciloleucel, Tisagenlecleucel,
Brexucabtagene Autoleucel, Lisocabtagene maraleucel, and Other
Drug Types; By Modality- Research and Commercialized; By Target
Antigen- CD19, CD22, BCMA, and Other Target Antigens; By IndicationLymphoma, Acute Lymphocytic Leukemia, Autoimmune Disorders, and
Other Indications; By End-User- Hospitals and Cancer Treatment
Centers
Regional Analysis
North America – The US, Canada, & Mexico; Western Europe –
Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria,
Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe
– Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe;
APAC – China, Japan, South Korea, India, Australia & New Zealand,
Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest
of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica,
& Rest of Latin America; The Middle East & Africa – Algeria, Egypt, Israel,
Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab
Emirates, & Rest of MEA
Competitive Landscape
Juno Therapeutics, Inc., Bristol-Myers Squibb Company, Bluebird Bio,
Inc., Gilead Sciences, Inc., Merck & Co., Inc. Pfizer, Inc. Sorrento
Therapeutics, Inc., Merck KGaA,Amgen Inc. Eureka Therapeutics Inc.,
Calyxt Inc., Autolus Therapeutics,CARsgen Therapeutics Co.Ltd.,Poseida
Therapeutics, Inc. , Fortress Biotech, Inc., and Other Key Players
Customization Scope
Customization for segments, region/country-level will be provided.
Moreover, additional customization can be done based on the
requirements.
Purchase Options
We have three licenses to opt for: Single User License, Multi-User
License (Up to 5 Users), Corporate Use License (Unlimited User and
Printable PDF)
Frequently Asked Questions (FAQ)
What is the size of the CAR-T Cell Therapies market in 2023?
The CAR-T Cell Therapies market size is USD 2.8 billion in 2023.
What is the projected CAGR at which the CAR-T Cell Therapies market is expected to
grow at?
The CAR-T Cell Therapies market is expected to grow at a CAGR of 13.8% (2024-2033).
List the segments encompassed in this report on the CAR-T Cell Therapies market?
Market.US has segmented the CAR-T Cell Therapies market by geographic (North
America, Europe, APAC, South America, and Middle East and Africa). CAR-T Cell
Therapies Market By Drug Type the market has been segmented into Axicabtagene
Cilolecucel, Tisagenlecleucel, Brezucabtagene Autoleucel, Brexucabtagene
Autoleucel, Lisocabtagene Maraleucel. By Modality the market has been segmented
into Research and Commercialized. By Target Antigen the market has been
segmented into CD19, CD22, BCMA, and Others.
List the key industry players of the CAR-T Cell Therapies market?
Juno Therapeutics Inc., Bristol-Myers Squibb Company, Bluebird Bio Inc., Gilead
Sciences Inc., Merck & Co. Inc., Pfizer Inc., Sorrento Therapeutics Inc., Merck KGaA,
Amgen Inc., Eureka Therapeutics Inc., Calyxt Inc., Autolus Therapeutics, CARsgen
Therapeutics Co.Ltd., Poseida Therapeutics Inc., Fortress Biotech Inc.
Which region is more appealing for vendors employed in the CAR-T Cell Therapies
market?
North America is expected to account for the highest revenue share of 61.49% and
boasting an impressive market value of USD 1.8 billion. Therefore, the CAR-T Cell
Therapies industry in North America is expected to garner significant business
opportunities over the forecast period.
Name the key areas of business for CAR-T Cell Therapies?
The US, Canada, India, China, UK, Japan, & Germany are key areas of operation for
the CAR-T Cell Therapies Market.
CAR-T Cell Therapies Market
Published date: Feb 2023
add_shopping_cart Buy Now
get_app Download Sample
Related Reports
Cell Counting Market
Live Cell Imaging Market
Cell Dissociation Market
Autologous Cell Therapy Market
Mesenchymal Stem Cells Market
Foosball Table Market
Digital Twins in Healthcare Market
Our Clients
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
SINGLE USER
MULTI USER
$6,000
$8,000
CORPORATE USER
$10,000
$3,999
$5,999
$6,999
USD / PER UNIT
USD / PER UNIT
USD / PER UNIT
SAVE 24%
SAVE 28%
SAVE 32%
Free Custumization
No
up to 10 hrs work
up to 30 hrs work
1 User
2-5 User
Unlimited
up to 20 hrs
up to 40 hrs
up to 50 hrs
Up to 20% off on next purchase
Up to 25% off on next purchase
Up to 30% off on next purchase
Buy Now ($ 3,999)
Buy Now ($ 5,999)
Buy Now ($ 6,999)
Accessibility
Analyst Support
Benefit
Lexington Avenue, Suite
location_on 420
300 New York City, NY 10170,
United States
phone +1 718 874 1545 (International)
phone +91 78878 22626 (Asia)
email inquiry@market.us
Find Help
Explore
Contact Us
About Us
How to Order
All Reports
Legal
Privacy Policy
Refund Policy
Frequently Asked Questions
Terms and Conditions
© 2025 Market.Us. All Rights Reserved.
All Sectors
Infographics
Statistics and Facts
Companies
Secured Payment Options